Alyeska Investment Group
FULC icon

Alyeska Investment Group’s Fulcrum Therapeutics FULC Stock Holding History

Alyeska Investment Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Buy
+1,328,449
New +$12.3M 0.03% 398
2024
Q3 		– Sell
-202,148
Closed -$1.25M – 590
2024
Q2 		$1.25M Hold
202,148
– – 0.01% 449
2024
Q1 		$1.91M Hold
202,148
– – 0.01% 379
2023
Q4 		$1.36M Hold
202,148
– – 0.01% 391
2023
Q3 		$898K Hold
202,148
– – 0.01% 425
2023
Q2 		$667K Buy
202,148
+50,000
+33% +$147K 0.01% 479
2023
Q1 		$434K Buy
+152,148
New +$1.36M ﹤0.01% 419
2021
Q1 		– Sell
-452,797
Closed -$5.3M – 767
2020
Q4 		$5.3M Buy
452,797
+244,040
+117% +$2.76M 0.07% 261
2020
Q3 		$1.66M Buy
+208,757
New +$2.51M 0.03% 368
2020
Q1 		– Sell
-75,551
Closed -$1.26M – 404
2019
Q4 		$1.26M Sell
75,551
-74,714
-50% -$714K 0.02% 319
2019
Q3 		$998K Buy
+150,265
New +$1.66M 0.01% 324

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Alyeska Investment Group's FULC Position: Q1 2026 in Review

Alyeska Investment Group opened a new position in Fulcrum Therapeutics (FULC) in Q1 2026: 1,328,449 shares worth $10.2M. The stake represents 0.03% of the portfolio and ranks #398 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in FULC as recently as Q2 2024.

Alyeska Investment Group first reported a position in FULC in Q3 2019 and has held it in 11 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Alyeska Investment Group held 1,328,449 shares of Fulcrum Therapeutics worth $10.2M as of Q1 2026.
  • Fulcrum Therapeutics was a new Alyeska Investment Group position in Q1 2026.
  • Fulcrum Therapeutics made up 0.03% of Alyeska Investment Group's portfolio in Q1 2026, its #398 holding.
  • Alyeska Investment Group first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 11 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.